Anaconda BioMed S.L. Appoints Dr. Tudor Jovin to its Scientific Advisory Board (SAB)
BARCELONA, Spain, Dec. 8, 2016 /PRNewswire/ -- Anaconda BioMed S.L., a pre-clinical stage medical device company focused on the development of the next generation neuro-thrombectomy system for the treatment of Acute Ischemic Stroke (AIS), announced the appointment of Tudor G. Jovin, MD to join its Scientific Advisory Board (SAB). The SAB is expected to serve as a strategic network of scientific and clinical experts to Anaconda BioMed S.L., as the company progresses the development of the ANCD BRAIN® to its clinical phase. The SAB is also expected to be an integral part of the company's strategy as it continues to assess opportunities to expand its pipeline. Dr. Jovin is a Professor of Neurology and Neurosurgery, Director of the UPMC Stroke Institute and Director of the UPMC Center for Neuroendovascular Therapy.
"We are honored and gratified to have Dr. Jovin, one of the leading authorities in the field of neuro-thrombectomy agree to join our SAB," said Anaconda BioMed S.L. CEO, Dr. Ofir Arad. "Anaconda BioMed will benefit from a leading SAB to navigate our development towards a successful clinical application."
"It is a major challenge to develop a 3rd Generation Advanced Thrombectomy Device. I have been following the Anaconda BioMed's team from early stage and they developed a promising and innovative thrombectomy system," said Dr. Jovin. "I am excited to join this team and am looking forward to reaching the clinical phase".
About Anaconda BioMed, S.L.
Anaconda BioMed S.L. (www.anaconda.bio), headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN®, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS). Every 2 seconds someone in the world is undergoing a stroke. Every 10 seconds someone in the world dies from a stroke. In the USA, there are about 690,000 annual incidences of AIS.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anaconda BioMed S.L.'s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements.
Contact:
Uri Fligil +34 936 397 710
[email protected]
Logo - http://photos.prnewswire.com/prnh/20161207/446724LOGO
SOURCE Anaconda BioMed, S.L.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article